History and evolution of US FD&C Act and related laws MCQs With Answer

Introduction: This quiz set focuses on the history and evolution of the United States Federal Food, Drug, and Cosmetic (FD&C) Act and its related laws, designed for M.Pharm students studying regulatory affairs. It traces key statutes, amendments and landmark decisions that shaped modern drug, device and food regulation — from the Pure Food and Drug Act (1906) to contemporary laws such as the FDA Amendments Act and Biologics Price Competition and Innovation Act. The questions emphasize legal milestones, regulatory concepts (adulteration, misbranding, new drug definitions), premarket pathways (NDA, ANDA, 510(k), PMA), and postmarket obligations critical for pharmacists and regulatory professionals. Use these MCQs to test and strengthen your understanding of regulatory history and practice.

Q1. Which early federal statute is considered the first major U.S. law addressing adulteration and misbranding of foods and drugs?

  • The Food, Drug, and Cosmetic Act of 1938
  • The Pure Food and Drug Act of 1906
  • The Kefauver-Harris Amendment of 1962
  • The Food Additives Amendment of 1958

Correct Answer: The Pure Food and Drug Act of 1906

Q2. The FD&C Act of 1938 introduced a major premarket requirement for new drugs. What was this requirement?

  • Proof of both safety and effectiveness before marketing
  • Mandatory color additive testing for all drugs
  • Evidence of safety (but not efficacy) before marketing
  • Automatic approval of drugs marketed before 1906

Correct Answer: Evidence of safety (but not efficacy) before marketing

Q3. Which amendment formally distinguished prescription (legend) drugs from over‑the‑counter drugs and permitted oral prescriptions and refills?

  • Durham‑Humphrey Amendment (1951)
  • Kefauver‑Harris Amendment (1962)
  • Orphan Drug Act (1983)
  • Food Additives Amendment (1958)

Correct Answer: Durham‑Humphrey Amendment (1951)

Q4. The Kefauver‑Harris Amendment of 1962 is historically important because it required which of the following for new drugs?

  • Proof of manufacturing by a U.S. company
  • Proof of both safety and efficacy before approval
  • Removal of all premarket review requirements
  • Automatic market exclusivity for five years

Correct Answer: Proof of both safety and efficacy before approval

Q5. Which 1958 amendment introduced the concept of “Generally Recognized as Safe” (GRAS) and required premarket safety for food additives?

  • Color Additives Amendment
  • Food Additives Amendment
  • Medical Device Amendments
  • Orphan Drug Act

Correct Answer: Food Additives Amendment

Q6. Which law (1976) established device classification, the 510(k) premarket notification pathway, and the PMA requirement?

  • Medical Device Amendments
  • Food, Drug, and Cosmetic Act (original 1938)
  • FDA Modernization Act
  • Hatch‑Waxman Act

Correct Answer: Medical Device Amendments

Q7. The Drug Price Competition and Patent Term Restoration Act (Hatch‑Waxman Act) of 1984 primarily created which important regulatory pathway?

  • Biologics 351(k) biosimilar pathway
  • Abbreviated New Drug Application (ANDA) for generics
  • Expanded PMA requirements for devices
  • OTC monograph repeal

Correct Answer: Abbreviated New Drug Application (ANDA) for generics

Q8. Which act provides incentives (tax credits, market exclusivity) to encourage development of drugs for rare diseases?

  • Orphan Drug Act (1983)
  • FDAMA (1997)
  • Food Additives Amendment (1958)
  • Medical Device Amendments (1976)

Correct Answer: Orphan Drug Act (1983)

Q9. Which program, established in 1992, required industry user fees to fund FDA drug application reviews and sped review timelines?

  • FDA Modernization Act
  • PDUFA (Prescription Drug User Fee Act)
  • Food Safety Modernization Act
  • Biologics Price Competition and Innovation Act

Correct Answer: PDUFA (Prescription Drug User Fee Act)

Q10. The Biologics Price Competition and Innovation Act (2009) primarily created which regulatory pathway?

  • ANDA pathway for small‑molecule generics
  • 510(k) device clearance
  • Biosimilar approval pathway (351(k))
  • PMA for biologic devices

Correct Answer: Biosimilar approval pathway (351(k))

Q11. Under the FD&C Act, which term refers to a product that fails to meet strength, quality or purity standards or is prepared/held under unsanitary conditions?

  • Misbranding
  • Adulteration
  • Counterfeiting
  • Monograph deviation

Correct Answer: Adulteration

Q12. Which Supreme Court decision and lower‑court precedent established the “responsible corporate officer” doctrine allowing criminal liability for corporate officers for FD&C violations?

  • United States v. Park (1975) and United States v. Dotterweich (1943)
  • Brown v. Board of Education (1954)
  • Marbury v. Madison (1803)
  • Roe v. Wade (1973)

Correct Answer: United States v. Park (1975) and United States v. Dotterweich (1943)

Q13. How does the FD&C Act commonly define a “new drug” in regulatory terms?

  • A drug marketed only outside the U.S.
  • A drug not generally recognized as safe and effective for its labeled use
  • Any herbal product
  • A drug that has been on the market for over 50 years

Correct Answer: A drug not generally recognized as safe and effective for its labeled use

Q14. What is the OTC monograph system?

  • A marketing exclusivity program for new prescription drugs
  • The FDA’s recipe book listing acceptable OTC active ingredients, doses and labeling that allow marketing without an NDA
  • A requirement that all OTC drugs must undergo PMA review
  • A postmarket surveillance registry for adverse events

Correct Answer: The FDA’s recipe book listing acceptable OTC active ingredients, doses and labeling that allow marketing without an NDA

Q15. Which regulatory submission demonstrates “substantial equivalence” for many moderate‑risk medical devices?

  • New Drug Application (NDA)
  • Biologics License Application (BLA)
  • 510(k) premarket notification
  • Abbreviated New Drug Application (ANDA)

Correct Answer: 510(k) premarket notification

Q16. Before initiating human clinical trials in the U.S., sponsors must file an IND. How long does the FDA have to review and raise a clinical hold after an IND submission?

  • 7 days
  • 30 days
  • 180 days
  • No review period — immediate start is permitted

Correct Answer: 30 days

Q17. The Kefauver‑Harris Amendments were prompted by which international tragedy that highlighted teratogenic risk?

  • Thalidomide birth defects
  • Chernobyl radiation exposure
  • HIV contaminated blood supply
  • SARS outbreak

Correct Answer: Thalidomide birth defects

Q18. Which amendment required premarket approval specifically for color additives used in foods, drugs and cosmetics?

  • Food Additives Amendment (1958)
  • Color Additives Amendment (1960)
  • Medical Device Amendments (1976)
  • FDAMA (1997)

Correct Answer: Color Additives Amendment (1960)

Q19. The Food Safety Modernization Act (FSMA) of 2011 shifted the focus of U.S. food law toward which approach?

  • Reactive, emphasizing recall after illness occurs
  • Export controls only
  • Proactive prevention to reduce contamination risks before problems arise
  • Removal of all HACCP requirements

Correct Answer: Proactive prevention to reduce contamination risks before problems arise

Q20. Which law granted FDA explicit authority to require Risk Evaluation and Mitigation Strategies (REMS) for certain drugs?

  • Prescription Drug User Fee Act (PDUFA) 1992
  • FDA Amendments Act (FDAAA) 2007
  • Hatch‑Waxman Act (1984)
  • Pure Food and Drug Act (1906)

Correct Answer: FDA Amendments Act (FDAAA) 2007

Leave a Comment

PRO
Ad-Free Access
$3.99 / month
  • No Interruptions
  • Faster Page Loads
  • Support Content Creators